BTIG Research Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock

Posted by Brian Himes on Sep 14th, 2026

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price target upped by BTIG Research from $39.00 to $40.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 92.83% from the company’s previous close.

A number of other equities research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a research note on Monday, August 17th. Wedbush boosted their price objective on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Finally, TD Cowen upgraded Cullinan Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.00.

View Our Latest Analysis on CGEM

Cullinan Therapeutics Stock Up 0.7%

Shares of CGEM stock traded up $0.15 during trading hours on Monday, hitting $20.74. 643,455 shares of the company’s stock were exchanged, compared to its average volume of 859,782. The firm has a 50 day moving average of $19.46 and a two-hundred day moving average of $16.43. The firm has a market cap of $1.34 billion, a P/E ratio of -6.68 and a beta of 0.02. Cullinan Therapeutics has a fifty-two week low of $5.68 and a fifty-two week high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). On average, equities analysts forecast that Cullinan Therapeutics will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 30,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $20.26, for a total value of $607,800.00. Following the sale, the insider directly owned 162,844 shares in the company, valued at $3,299,219.44. This trade represents a 15.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 46,000 shares of company stock valued at $922,920. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Large investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new stake in Cullinan Therapeutics during the 2nd quarter worth $25,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Cullinan Therapeutics by 62.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock valued at $28,000 after buying an additional 1,036 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in Cullinan Therapeutics during the fourth quarter worth about $31,000. Allworth Financial LP bought a new stake in shares of Cullinan Therapeutics during the second quarter worth approximately $53,000. Finally, Quantbot Technologies LP bought a new stake in Cullinan Therapeutics in the 2nd quarter valued at $53,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

Key Headlines Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

Positive Sentiment: In the Phase 3 REZILIENT3 trial, first-line zipalertinib combined with chemotherapy delivered a six-month improvement in median progression-free survival versus chemotherapy alone in patients with EGFR exon 20 insertion-positive non-small cell lung cancer. The result strengthens the potential commercial value of Cullinan’s lead drug and supports its regulatory strategy. REZILIENT3 Phase 3 trial results
Neutral Sentiment: Cullinan hosted a virtual analyst and investor event to discuss the interim REZILIENT3 data presented at the IASLC 2026 World Conference on Lung Cancer. Management participation provides investors with additional detail on the efficacy, safety profile, and development path for zipalertinib. Cullinan investor event announcement
Neutral Sentiment: The shareholder and analyst call transcript may clarify how management views the interim findings, remaining regulatory requirements, and the broader outlook for zipalertinib. Investors are likely focused on whether the results can support approval and meaningful adoption in a competitive lung-cancer market. Cullinan shareholder and analyst call transcript
Negative Sentiment: Despite the six-month progression-free-survival benefit, reports indicated that CGEM shares fell as investors assessed the full trial package. The negative reaction implies concerns about the interim nature of the data, the magnitude of the benefit relative to expectations, or uncertainty around regulatory and commercial execution.

Cullinan Therapeutics Company Profile

(Get Free Report)

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.